Market Overview

GlycoMimetics to Host 2018 Investor/Analyst Meeting at 60th ASH Annual Meeting on December 3, 2018


GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that it will host and
webcast an investor/analyst meeting and update at the 60th American
Society of Hematology (ASH) Annual Meeting in San Diego, on December 3
at 6 a.m. PT. Daniel J. DeAngelo, MD, PhD, Director of Clinical
and Translational Research, Adult Leukemia Program, Dana-Farber Cancer
Institute/Brigham and Women's Hospital, Associate Professor of Medicine,
Harvard Medical School, who served as lead investigator of the
GlycoMimetics' recently completed Phase 1/2 clinical trial of
uproleselan in acute myeloid leukemia patients, will recap and provide
perspective on his December 2 oral presentation at the ASH meeting,
highlighting the trial's findings. GlycoMimetics management will review
additional posters from the ASH meeting.

The investor/analyst event will be webcast beginning at 6:15 a.m. PT.
The dial-in number for the event is (844) 413-7154 (U.S. and Canada) or
(216) 562-0466 (international) with passcode 9779654. To access the live
audio webcast, or the subsequent archived recording, visit the
"Investors - Events & Presentations" section of the
GlycoMimetics website at
The webcast will be recorded and available for replay on
the GlycoMimetics website for 30 days following the call.

Investors/analysts are requested to pre-register for the private
in-person event at
The event will be held at Hard Rock Hotel San Diego in the Celebrate
Room, 207 Fifth Avenue, San Diego. On-site inquiries will be handled by
Shari Annes, (650) 888-0902, by text or phone.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. GlycoMimetics' most advanced drug candidate,
rivipansel, a pan-selectin antagonist, is being developed for the
treatment of vaso-occlusive crisis in sickle cell disease and is being
evaluated in a Phase 3 clinical trial being conducted by its strategic
collaborator, Pfizer. GlycoMimetics' wholly owned drug candidate,
uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2
clinical trial as a potential treatment for AML and is currently being
evaluated in a company-sponsored Phase 3 trial in relapsed/refractory
AML. The U.S. Food and Drug Administration granted uproleselan
breakthrough therapy designation for the treatment of adult AM) patients
with relapsed/refractory disease. GlycoMimetics has also completed a
Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined
CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more at

View Comments and Join the Discussion!